KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash & Equivalents (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash & Equivalents for 13 consecutive years, with $199.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 39.56% to $199.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $199.2 million through Dec 2025, up 39.56% year-over-year, with the annual reading at $199.2 million for FY2025, 39.56% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $199.2 million at Xenon Pharmaceuticals, down from $555.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $555.3 million in Q3 2025, with the low at $57.2 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $144.8 million, with a median of $110.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 82.55% in 2023, then soared 533.7% in 2025.
  • Over 5 years, Cash & Equivalents stood at $175.7 million in 2021, then crashed by 67.42% to $57.2 million in 2022, then surged by 159.67% to $148.6 million in 2023, then decreased by 3.99% to $142.7 million in 2024, then surged by 39.56% to $199.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $199.2 million, $555.3 million, and $135.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.